Adjuvant chemotherapy for resected colorectal cancer metastases: Literature review and meta-analysis

Table 1 Adjuvant systemic chemotherapy after primary resectable colorectal cancer

Trials	No. of patients	Schedules	DFS	P value	OS	P value
Oxaliplatin-based regimes
X-ACT	1987	CAPECITABINE (1004)	64.2%	0.12	81.3%	0.07
(Twelves et al[32], 2005)		5FU/LV (983)	60.6%		77.6%
NSABP C-07	2407	5FU/LV (1207)	67.0%	0.0034	-	-
(Kuebler et al[30], 2007)		FLOX (1200)	73.2%
MOSAIC	2246	5FU/LV (1123)	67.4%	0.003	68.7%	0.46
(André et al[29], 2009)		FOLFOX4 (1123)	73.3%		78.5%
XELOXA	1886	XELOX (944)	70.9%	0.045	77.6%	0.15
(Haller et al[31], 2011)		5FU/LV (942)	66.5%		74.2%
Irinotecan-based regimes
CALGB-89803	1264	Irinotecan + 5FU/LV (635)	59.0%	0.85	64.0%	0.74
(Saltz et al[35], 2007)		5FU/LV (629)	61.0%		67.0%
PETACC-3	2982	Irinotecan + 5FU/LV (1485)	56.7%	0.106	73.6%	0.094
(Van Cutsem et al[36], 2009)		5FU/LV (1497)	54.3%		71.3%
Bevacizumab + chemotherapy
NSABP C-08	2710	FOLFOX6 + Bevacizumab (1354)	77.4%	0.15	-	-
(Allegra et al[37], 2011)		FOLFOX6 (1356)	75.5%
AVANT	2867	FOLFOX4 + Bevacizumab (960)	73.0%	0.07	81.0%	0.02
(de Gramont et al[38], 2012)		FOLFOX4 (955)	76.0%		85.0%
		XELOX + Bevacizumab (952)	75.0%	0.44	82.0%	0.21
Cetuximab + chemotherapy
NCCTG NO147	2686	FOLFOX6 + Cetuximab (1349)	71.5%	0.08	72.5%	0.03
(Alberts et al[41], 2012)		FOLFOX6 (1337)	74.6%		86.2%
PETACC-8	337	FOLFOX4 + Cetuximab (169)	60.45	0.60	46.0%	0.064
(Taieb et al[42], 2012)		FOLFOX4 (168)	60.7%		36.0%
Oral flupropyrimidine in monotherapy
JCOG02051	1092	5-FU/LV (550)	74.3%	0.0236	-	-
(Shimada et al[33], 2014)		UFT/LV (551)	73.6%
ACT-CC1	1518	S-1 (758)	75.5%	< 0.01	-	-
(Yoshida et al[34], 2014)		UFT/LV (760)	72.5%

¹These trials were randomized, controlled non-inferiority studies. 5-FU/LV: 5-fluorouracil/leucovorin; FOLFOX: 5-FU/LV plus oxaliplatin; DFS: Disease-free survival; OS: Overall survival; UFT: Tegafur-uracil.